Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SUPERFILE, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to encryption.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF PROTON THERAPY via FORBES-TATE
2026 · third_quarter · Q3
Source: Senate LDA
| VIRPAX PHARMACEUTICALS |
| 14 |
| 2019–2022 |
| EMERGENT BIOSOLUTIONS | 13 | 2019–2021 |
| ADAPT PHARMA INC. | 12 | 2016–2018 |
| ASSURED GUARANTY MUNICIPAL CORP. | 12 | 2019–2022 |
| ULTRAGENYX PHARMACEUTICAL | 12 | 2019–2022 |
| GOLDMAN EDWARDS | 11 | 2020–2022 |
| NOVARTIS, INC. | 11 | 2019–2021 |
| PRIMMUNE THERAPEUTICS | 11 | 2020–2022 |
| REGENESIS | 11 | 2020–2022 |
| BIO-RAD LABORATORIES | 10 | 2020–2022 |
| HALOZYME THERAPEUTICS, INC. | 10 | 2019–2021 |
| VIR BIOTECHNOLOGY, INC. | 10 | 2020–2022 |
| METRC LLC | 8 | 2019–2021 |
| AEON BIOPHARMA | 7 | 2019–2020 |
| EVOLUS BEAUTY | 7 | 2019–2020 |
| MOLINA HEALTHCARE, INC. | 7 | 2020–2021 |
| GRODAN INC. | 6 | 2020–2021 |
| TARSUS PHARMACEUTICALS | 6 | 2025–2026 |
| SAFETYSPECT | 5 | 2025–2026 |
| BELLEROPHON THERAPEUTICS | 4 | 2020 |
| UROVANT SCIENCES | 4 | 2020 |
| KAHALA BIOSCIENCES | 3 | 2020 |
| PRIVAPATH DIAGNOSTICS, INC. DBA LET'S GET CHECKED, INC. | 3 | 2020 |
| SUPERFILE, INC. | 3 | 2026 |
| SYNDAX PHARMACEUTICALS | 3 | 2020 |
| ABYRX, INC. | 2 | 2020 |
| LILLY USA, LLC | 1 | 2020 |
| NATIONAL ASSOCIATION OF PROTON THERAPY | 1 | 2026 |
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
ROCR Value Based Program Act
Client: NATIONAL ASSOCIATION OF PROTON THERAPY · Firm: FORBES-TATE
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
American Rescue Plan Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
American Rescue Plan Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
American Rescue Plan Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues regarding implementation of provisions related to higher education, research, and student aid relief in the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to emergency funding for institutions of higher education in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to college athletics, including name, image, and likeness.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
American Rescue Plan Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, S. 610 - Protecting Medicare & American Farmers from Sequester Cuts Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
American Rescue Plan Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to emergency funding for institutions of higher education in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to college athletics, including name, image, and likeness.
American Rescue Plan Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues regarding implementation of provisions related to higher education, research, and student aid relief in the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to emergency funding for institutions of higher education in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to college athletics, including name, image, and likeness.
American Rescue Plan Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to emergency funding for institutions of higher education in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to college athletics, including name, image, and likeness.
American Rescue Plan Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
State Opioid Response Grant Authorization Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone.
State Opioid Response Grant Authorization Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
State Opioid Response Grant Authorization Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
State Opioid Response Grant Authorization Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
Medicare Sequester COVID Moratorium Act
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
Medicare Sequester COVID Moratorium Act
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
Medicare Sequester COVID Moratorium Act
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022, provisions related to biological and chemical defense and access to naloxone; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act.
Infrastructure Investment and Jobs Act
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues regarding FY 2022 Transportation Housing & Urban Development Appropriations as related to University transportation centers and transportation research; H.R. 3684 - INVEST in America Act.
Infrastructure Investment and Jobs Act
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues regarding FY 2022 Transportation Housing & Urban Development Appropriations as related to University transportation centers and transportation research; H.R. 3684 - INVEST in America Act.
Infrastructure Investment and Jobs Act
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to funding for research, including the University Transportation Centers Program, in PL 117-58, the Infrastructure Investment and Jobs Act; Issues regarding FY 2022 Transportation Housing & Urban Development Appropriations as related to University transportation centers and transportation research; Infrastructure Investment and Jobs Act H.R. 3684 - INVEST in America Act.
National Defense Authorization Act for Fiscal Year 2022
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022, provisions related to biological and chemical defense and access to naloxone; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act.
National Defense Authorization Act for Fiscal Year 2022
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone.
National Defense Authorization Act for Fiscal Year 2022
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022, provisions related to biological and chemical defense and access to naloxone; S. 4231 (116th Congress) - Preparing for the Next Pandemic Act; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines.
National Defense Authorization Act for Fiscal Year 2022
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues regarding FY 2022 Department of Defense Appropriations as related to defense research; Issues pertaining to defense research funding and research security in H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022.
National Defense Authorization Act for Fiscal Year 2022
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
Preventing Overdoses and Saving Lives Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone.
Preventing Overdoses and Saving Lives Act of 2021
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
Emergency Support for Substance Use Disorders Act
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
Emergency Support for Substance Use Disorders Act
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
United States Innovation and Competition Act of 2021
Client: UNIVERSITY OF SOUTHERN CALIFORNIA · Firm: FORBES-TATE
Issues related to scientific research in the S.1260 - United States Innovation and Competition Act of 2021.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
Emergency Support for Substance Use Disorders Act
Client: EMERGENT BIOSOLUTIONS · Firm: FORBES-TATE
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.
Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.
Issues related to continued access to and provider reimbursement for proton beam therapy; Issues related to the Fiscal Year 2027 Labor-HHS appropriations process.
Issues pertaining to veterans' access to proton therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
SUPERFILE, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to encryption.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUPERFILE, INC. via FORBES-TATE
2026 · second_quarter · RR
Issues related to IT security.
TARSUS PHARMACEUTICALS via FORBES-TATE
2026 · first_quarter · Q1
Issues related to education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
2025 · fourth_quarter · Q4
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
TARSUS PHARMACEUTICALS via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Q3
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
TARSUS PHARMACEUTICALS via FORBES-TATE
2025 · third_quarter · Q3
Issues related to Education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Q2
Issues related to FY25/FY26 Appropriations; Issues related to the reintroduction of the Protecting Older Americans Act; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to the reintroduction of the Protecting Older Americans Act; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to the reintroduction of the Protecting Older Americans Act; Issues related to funding involving food safety and security and medical research.
TARSUS PHARMACEUTICALS via FORBES-TATE
2025 · second_quarter · Q2
Issues related to Education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TARSUS PHARMACEUTICALS via FORBES-TATE
2025 · first_quarter · Q1
Issues related to Education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Q1
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
TARSUS PHARMACEUTICALS via FORBES-TATE
2025 · first_quarter · RR
Education and advocacy related to life science products and pipeline.
VIRPAX PHARMACEUTICALS via FORBES-TATE
2022 · second_quarter · Q2
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2022 · second_quarter · Q2
Issues related to COVID funding.
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · second_quarter · Q2
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRIMMUNE THERAPEUTICS via FORBES-TATE
2022 · second_quarter · Q2
Issues related to COVID-19 response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOLDMAN EDWARDS via FORBES-TATE
2022 · second_quarter · Q2
Issues related to federal Information and Communications Technology (ICT) contracts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIO-RAD LABORATORIES via FORBES-TATE
2022 · second_quarter · Q2
Issues related to biomedical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2022 · second_quarter · Q2
Issues regarding Puerto Rico's Medicaid program.
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies.
Issues related to supply chain and logistics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIRPAX PHARMACEUTICALS via FORBES-TATE
2022 · first_quarter · Q1
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2022 · first_quarter · Q1
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERDE TECHNOLOGIES via FORBES-TATE
2022 · first_quarter · 1T
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · first_quarter · Q1
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS via FORBES-TATE
2022 · first_quarter · 1T
Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases.
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases; Issues related to newborn screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENESIS via FORBES-TATE
2022 · first_quarter · 1T
Issues related to Appropriations.
Issues related to PFAS substances.
Issues related to PFAS substances; Issues regarding implementation of the National Defense Authorization Act for Fiscal Year 2021 (Public Law No: 116-283).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIMMUNE THERAPEUTICS via FORBES-TATE
2022 · first_quarter · Q1
Issues related to COVID-19 response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Q1
Issues related to the opioid crisis; Issues related to NIH funding; Issues related to wound care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOLDMAN EDWARDS via FORBES-TATE
2022 · first_quarter · Q1
Issues related to federal Information and Communications Technology (ICT) contracts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIO-RAD LABORATORIES via FORBES-TATE
2022 · first_quarter · Q1
Issues related to biomedical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2022 · first_quarter · Q1
Issues related to supply chain and logistics.
Issues regarding Puerto Rico's Medicaid program.
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF SOUTHERN CALIFORNIA via FORBES-TATE
2021 · fourth_quarter · 4T
Issues related to FY 2022 Defense Appropriations; Issues related to funding for university research and UARCs.
Issues related to emergency funding for institutions of higher education in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to college athletics, including name, image, and likeness.
Issues regarding FY 2022 Department of Defense Appropriations as related to defense research; Issues pertaining to defense research funding and research security in H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022.
VIRPAX PHARMACEUTICALS via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2021 · fourth_quarter · Q4
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERDE TECHNOLOGIES via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENESIS via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to Appropriations.
Issues related to PFAS substances.
Issues related to PFAS substances; Issues regarding implementation of the National Defense Authorization Act for Fiscal Year 2021 (Public Law No: 116-283).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIMMUNE THERAPEUTICS via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to COVID-19 response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Q4
Issues related to the opioid crisis; Issues related to NIH funding; Issues related to wound care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · 4T
Issues related to Mental health and Alzheimer's disease research; Issues related to the Food and Drug Administration; Issues related to protected class drug. Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Issues related to prescription drug pricing; Issues related to proposed regulations affecting Medicare Part D. Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260). Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
GOLDMAN EDWARDS via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to federal Information and Communications Technology (ICT) contracts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMERGENT BIOSOLUTIONS via FORBES-TATE
2021 · fourth_quarter · Q4
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022, provisions related to biological and chemical defense and access to naloxone; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act.
BIO-RAD LABORATORIES via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to biomedical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2021 · fourth_quarter · Q4
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies.
Issues regarding Puerto Rico's Medicaid program.
Issues related to supply chain and logistics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS via FORBES-TATE
2021 · fourth_quarter · Q4
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases; Issues related to newborn screening.
Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIRPAX PHARMACEUTICALS via FORBES-TATE
2021 · third_quarter · Q3
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2021 · third_quarter · Q3
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERDE TECHNOLOGIES via FORBES-TATE
2021 · third_quarter · Q3
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2021 · third_quarter · Q3
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SORRENTO THERAPEUTICS, INC. via FORBES-TATE
2021 · third_quarter · 3T
Issues related to FDA approval and NIH funding issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENESIS via FORBES-TATE
2021 · third_quarter · Q3
Issues related to Appropriations.
Issues related to PFAS substances; Issues regarding implementation of the National Defense Authorization Act for Fiscal Year 2021 (Public Law No: 116-283).
Issues related to PFAS substances.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF SOUTHERN CALIFORNIA via FORBES-TATE
2021 · third_quarter · Q3
Issues regarding FY 2022 Transportation Housing & Urban Development Appropriations as related to University transportation centers and transportation research; H.R. 3684 - INVEST in America Act.
Issues regarding FY 2022 Department of Defense Appropriations as related to defense research; Issues related to high-skilled immigration.
Issues related to emergency funding for institutions of higher education in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to college athletics, including name, image, and likeness.
SAREPTA THERAPEUTICS via FORBES-TATE
2021 · third_quarter · Q3
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases.
Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases; Issues related to newborn screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIMMUNE THERAPEUTICS via FORBES-TATE
2021 · third_quarter · Q3
Issues related to COVID-19 response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2021 · third_quarter · Q3
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Q3
Issues related to the opioid crisis; Issues related to NIH funding; Issues related to wound care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Q3
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260). Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Issues related to prescription drug pricing; Issues related to proposed regulations affecting Medicare Part D. Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Issues related to Mental health and Alzheimer's disease research; Issues related to the Food and Drug Administration; Issues related to protected class drug. Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
HALOZYME THERAPEUTICS, INC. via FORBES-TATE
2021 · third_quarter · Q3
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOLDMAN EDWARDS via FORBES-TATE
2021 · third_quarter · Q3
Issues related to federal Information and Communications Technology (ICT) contracts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMERGENT BIOSOLUTIONS via FORBES-TATE
2021 · third_quarter · Q3
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone.
H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022, provisions related to biological and chemical defense and access to naloxone; S. 4231 (116th Congress) - Preparing for the Next Pandemic Act; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
BIO-RAD LABORATORIES via FORBES-TATE
2021 · third_quarter · Q3
Issues related to biomedical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2021 · third_quarter · Q3
Issues regarding Puerto Rico's Medicaid program.
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies.
Issues related to supply chain and logistics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF SOUTHERN CALIFORNIA via FORBES-TATE
2021 · second_quarter · Q2
Issues related to FY 2022 Defense Appropriations; Issues related to funding for university research and UARCs.
Issues related to immigration policy, including high-skilled immigration and H-1B Visas; Issues related to student visa processing.
Issues regarding FY 2022 Department of Defense Appropriations as related to defense research; Issues related to high-skilled immigration.
VIRPAX PHARMACEUTICALS via FORBES-TATE
2021 · second_quarter · Q2
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2021 · second_quarter · Q2
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERDE TECHNOLOGIES via FORBES-TATE
2021 · second_quarter · Q2
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2021 · second_quarter · Q2
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SORRENTO THERAPEUTICS, INC. via FORBES-TATE
2021 · second_quarter · Q2
Issues related to FDA approval and NIH funding issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENESIS via FORBES-TATE
2021 · second_quarter · Q2
Issues related to PFAS substances.
Issues related to PFAS substances.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIMMUNE THERAPEUTICS via FORBES-TATE
2021 · second_quarter · Q2
Issues related to COVID-19 response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2021 · second_quarter · Q2
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Q2
Issues related to the opioid crisis; Issues related to NIH funding; Issues related to wound care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
METRC LLC via FORBES-TATE
2021 · second_quarter · Q2
Issues related to agriculture and technology in emerging industries.
Issues related to agriculture and technology in emerging industries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Q2
Issues related to prescription drug pricing; Issues related to proposed regulations affecting Medicare Part D.
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Issues related to Mental health and Alzheimer's disease research; Issues related to the Food and Drug Administration; Issues related to protected class drug.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HALOZYME THERAPEUTICS, INC. via FORBES-TATE
2021 · second_quarter · Q2
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOLDMAN EDWARDS via FORBES-TATE
2021 · second_quarter · Q2
Issues related to federal Information and Communications Technology (ICT) contracts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMERGENT BIOSOLUTIONS via FORBES-TATE
2021 · second_quarter · Q2
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
National Defense Authorization Act (NDAA) for FY22, provisions related to biological and chemical defense and access to naloxone; S. 4231 (116th Congress) - Preparing for the Next Pandemic Act; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
BIO-RAD LABORATORIES via FORBES-TATE
2021 · second_quarter · Q2
Issues related to biomedical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2021 · second_quarter · Q2
Issues regarding Puerto Rico's Medicaid program.
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market.
Issues related to supply chain and logistics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS via FORBES-TATE
2021 · second_quarter · Q2
Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases; Issues related to newborn screening.
Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases.
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via FORBES-TATE
2021 · second_quarter · Q2
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
UNIVERSITY OF SOUTHERN CALIFORNIA via FORBES-TATE
2021 · first_quarter · Q1
Issues regarding implementation of provisions related to higher education, research, and student aid relief in the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to emergency funding for institutions of higher education in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to college athletics, including name, image, and likeness.
Issues related to college athletics, including name, image, and likeness.
Issues regarding FY 2022 Department of Defense Appropriations as related to defense research; Issues related to high-skilled immigration.
VIRPAX PHARMACEUTICALS via FORBES-TATE
2021 · first_quarter · Q1
Issues related to the opioid crisis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2021 · first_quarter · Q1
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERDE TECHNOLOGIES via FORBES-TATE
2021 · first_quarter · Q1
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2021 · first_quarter · Q1
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SORRENTO THERAPEUTICS, INC. via FORBES-TATE
2021 · first_quarter · Q1
Issues related to FDA approval and NIH funding issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENESIS via FORBES-TATE
2021 · first_quarter · Q1
Issues related to PFAS substances.
Issues related to PFAS substances.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIMMUNE THERAPEUTICS via FORBES-TATE
2021 · first_quarter · Q1
Issues related to COVID-19 response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMERGENT BIOSOLUTIONS via FORBES-TATE
2021 · first_quarter · Q1
National Defense Authorization Act (NDAA) for FY22, provisions related to biological and chemical defense and access to naloxone; S. 4231 (116th Congress) - Preparing for the Next Pandemic Act; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines.
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
MOLINA HEALTHCARE, INC. via FORBES-TATE
2021 · first_quarter · Q1
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Q1
Issues related to the opioid crisis; Issues related to NIH funding; Issues related to wound care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
METRC LLC via FORBES-TATE
2021 · first_quarter · Q1
Issues related to agriculture and technology in emerging industries.
Issues related to agriculture and technology in emerging industries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Q1
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Issues related to Mental health and Alzheimer's disease research; Issues related to the Food and Drug Administration; Issues related to protected class drug.
Issues related to prescription drug pricing; Issues related to proposed regulations affecting Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIO-RAD LABORATORIES via FORBES-TATE
2021 · first_quarter · Q1
Issues related to biomedical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HALOZYME THERAPEUTICS, INC. via FORBES-TATE
2021 · first_quarter · Q1
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSURED GUARANTY MUNICIPAL CORP. via FORBES-TATE
2021 · first_quarter · Q1
Issues related to supply chain and logistics.
Issues regarding Puerto Rico's Medicaid program.
Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Filing targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to H.R. 5115/S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Filing targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to S. 2703 - Protecting Older Americans Act of 2025; Issues related to funding involving food safety and security and medical research.
Filing targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to FY25/FY26 Appropriations; Issues related to the reintroduction of the Protecting Older Americans Act; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to the reintroduction of the Protecting Older Americans Act; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to the reintroduction of the Protecting Older Americans Act; Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; Issues related to the reintroduction of the Protecting Older Americans Act; Issues related to funding involving food safety and security and medical research.
Filing targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Issues related to FY25/FY26 Appropriations; H.R.4120/S.1979 - Protecting Older Americans Act (118th Congress); Issues related to funding involving food safety and security and medical research.
Filing targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to OSHA and private employer vaccine mandates.
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, S. 610 - Protecting Medicare & American Farmers from Sequester Cuts Act.
Issues related to funding for research, including the University Transportation Centers Program, in PL 117-58, the Infrastructure Investment and Jobs Act; Issues regarding FY 2022 Transportation Housing & Urban Development Appropriations as related to University transportation centers and transportation research; Infrastructure Investment and Jobs Act H.R. 3684 - INVEST in America Act.
Issues related to scientific research in the S.1260 - United States Innovation and Competition Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to immigration policy, including high-skilled immigration and H-1B Visas; Issues related to student visa processing.
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
Issues related to FY 2022 Defense Appropriations; Issues related to funding for university research and UARCs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding implementation of provisions related to higher education, research, and student aid relief in the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to emergency funding for institutions of higher education in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to college athletics, including name, image, and likeness.
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
Issues related to college athletics, including name, image, and likeness.
Issues regarding FY 2022 Transportation Housing & Urban Development Appropriations as related to University transportation centers and transportation research; H.R. 3684 - INVEST in America Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to immigration policy, including high-skilled immigration and H-1B Visas; Issues related to student visa processing.
Issues regarding FY 2022 Transportation Housing & Urban Development Appropriations as related to University transportation centers and transportation research.
Issues related to healthcare and academic medical centers; Issues regarding hospital funding in H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to telemedicine; Issues related to Medicare sequester, including H.R. 315 - Medicare Sequester COVID Moratorium Act.
Issues related to FY 2022 Defense Appropriations; Issues related to funding for university research and UARCs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE